Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by impaired phagocyte killing of intracellular pathogens. This leads to a predisposition to recurrent and potentially life-threatening bacterial and fungal infections and, occasionally, a variety of intestinal manifestations, from granulomata and obstruction, through to an inflammatory bowel-like syndrome. 1 We report the management of a boy with a life-threatening episode of toxic megacolon and associated fistula.
This boy, with a family history of CGD, was diagnosed as having the condition by the nitro blue tetrazolium (NBT) test. Along with recurrent infections, he developed inflammatory bowel disease in association with his CGD requiring frequent hospitalization and maintenance prednisolone to control symptoms. He had severe growth retardation resistant to growth hormone.
At the age of 11 years, he developed a large abscess on the left flank, resulting in fistulation from the colon to the skin. Several months treatment with antibiotics, steroids, granulocyte infusions and total parenteral nutrition failed to heal the fistula, and it was decided that his only chance for survival was an unrelated donor stem cell transplant (no sibling donor available); the parents were counseled regarding the high-risk nature of the procedure. The transplant involved using a minimally ablative conditioning protocol consisting of fludarabine (30 mg/m 2 Â 5, days À7 to À3), Campath-1H (0.2 mg/ kg Â 4, days À7 to À4) and melphalan (140 mg/m 2 , day À2), and a donation of 7.0 Â 10 8 bone marrow-derived, mononuclear cells per kilogram of recipient body weight; cyclosporin A was used as GVHD prophylaxis. Neutrophil engraftment occurred on day þ 10 and he became platelet transfusion independent on day þ 11. Both donor and recipient were cytomegalovirus (CMV) positive and CMV reactivation was detected on day þ 19, treated with ganciclovir.
He had full donor engraftment and neutrophil function was normal by NBT testing. At 2 months following the transplant, the fistula was healed and bowel symptoms improved; he started to gain weight.
At 4 months post transplant, he developed immunemediated pancytopenia, and secondary graft rejection was diagnosed with rapidly falling levels of recipient DNA, despite cessation of cyclosporin. The period of normal neutrophil function had led to such a vast improvement in the patient's condition that the decision was taken to proceed to a myeloablative transplant using the original donor conditioned with Campath-1H (0.2 mg/kg Â 5, days À7 to À3), cyclophosphamide (60 mg/kg Â 2, days À6 and À5) and TBI with cyclosporin A and short-course methotrexate GVHD prophylaxis. A peripheral bloodderived mononuclear cell dose of 4.2 Â 10 8 per kilogram recipient body weight was infused. Neutrophil engraftment occurred on day þ 19 and platelet independence on day þ 18. Again CMV reactivation was the major post transplant complication. At 10 months, he has full donor engraftment, normal neutrophil function, no GVHD, inflammatory bowel symptoms or signs of graft rejection.
CGD causes significant morbidity and mortality through recurrent infections and chronic inflammation. The use of prophylactic antimicrobials has led to improved survival, but breakthrough infections still occur.
2 Gamma-interferon has been shown to reduce the frequency of infective episodes, 3 but is expensive, has significant side effects and is not generally considered first-line therapy. Gene therapy is a future possibility, 4 but at present BMT remains the only curative option for these patients. 5 In common with other non-T-cell, immuno-deficient, genetic diseases, there is a high risk of graft failure and initial attempts at transplantation led to incomplete engraftment, but an increase in conditioning intensity has led to improved success rates. 6 This intensive conditioning limits the availability of the treatment to those patients without comorbidity, although there are reports of BMT being used as therapy in CGD with noncontrollable infections. 7 Reduced-intensity conditioning (RIC) could open the option of a stem cell procedure to patients with pre-existing organ damage, but the high risk of rejection limits its usefulness. Donor T-cell infusions have been employed to strengthen engraftment in these situations, 8 but the graft can be lost very rapidly. In this case, conventional therapy had failed to resolve the colonic disease and fistula and the patient was fading. BMT as salvage therapy was decided upon, in consultation with the family, and RIC transplant was considered the safer procedure. Engraftment was rapidly achieved with minimal complication and the functional neutrophils were able to heal the fistula before the graft was rejected. Rejection occurred via an antibody-mediated process and chimerism switched from 100% donor to all recipient within 3 weeks, despite reduction of immunosuppression. A full-intensity transplant could then be tolerated owing to the greatly improved physical condition of the patient.
We have shown that a reduced-intensity transplant is a useful procedure to provide functional phagocytes in a case of resistant infection/inflammation, but we see its limitations in terms of rapid rejection and counseling of patients should include this risk and need for a possible second procedure. 
